These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18545754)

  • 1. [Cost-effectiveness analysis of renal replacement therapies: how should we design research on these interventions in Brazil?].
    Sancho LG; Dain S
    Cad Saude Publica; 2008 Jun; 24(6):1279-90. PubMed ID: 18545754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost comparison of kidney transplant versus dialysis in Brazil.
    Silva SB; Caulliraux HM; Araújo CA; Rocha E
    Cad Saude Publica; 2016 Jun; 32(6):. PubMed ID: 27383457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic evaluations: the special case of end-stage renal disease treatment.
    Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
    Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal Dialysis as the Dialysis Initial Modality of Choice for Renal Replacement Therapy Initiation: Moving from "Why" to "Why Not".
    Subramanian S; Javaid MM
    Blood Purif; 2017; 44(2):106-107. PubMed ID: 28448966
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost effectiveness of renal provision in the UK.
    Haycox A; Jones D
    J Manag Med; 1996; 10(1):6-15. PubMed ID: 10162928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
    Zhang H; Zhang C; Zhu S; Ye H; Zhang D
    BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of renal replacement therapy by transplant in a system of bundled payment of dialysis.
    Rocha MJ; Ferreira S; Martins LS; Almeida M; Dias L; Pedroso S; Henriques AC; Almeida R; Cabrita A
    Clin Transplant; 2012; 26(4):529-31. PubMed ID: 22211715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost effectiveness analysis of the treatment of end stage renal failure.
    Croxson BE; Ashton T
    N Z Med J; 1990 Apr; 103(888):171-4. PubMed ID: 2109846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritoneal dialysis is the best cost-effective alternative for maintaining dialysis treatment.
    Arrieta J; Rodríguez-Carmona A; Remón C; Pérez-Fontán M; Ortega F; Sánchez Tomero JA; Selgas R
    Nefrologia; 2011; 31(5):505-13. PubMed ID: 21959716
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics of dialysis and renal transplantation in the developing world.
    Chugh KS; Jha V; Chugh S
    Transplant Proc; 1999 Dec; 31(8):3275-7. PubMed ID: 10616473
    [No Abstract]   [Full Text] [Related]  

  • 11. A systematic review and quality assessment of economic evaluations of kidney replacement therapies in end-stage kidney disease.
    Nyokabi P; Youngkong S; Bagepally BS; Okech T; Chaikledkaew U; McKay GJ; Attia J; Thakkinstian A
    Sci Rep; 2024 Oct; 14(1):23018. PubMed ID: 39362958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
    Bayani DBS; Almirol BJQ; Uy GDC; Taneo MJS; Danguilan RS; Arakama MI; Lamban AB; de Leon D; Pamugas GEP; Luz AC; Teerawatananon Y
    Nephrology (Carlton); 2021 Feb; 26(2):170-177. PubMed ID: 33207027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making peritoneal dialysis and home hemodialysis more economically viable.
    Sullivan JD
    Nephrol News Issues; 2006 Jul; 20(8):54, 56-8. PubMed ID: 16859233
    [No Abstract]   [Full Text] [Related]  

  • 14. End-stage renal disease therapy: an American success story.
    Friedman EA
    JAMA; 1996 Apr; 275(14):1118-22. PubMed ID: 8601932
    [No Abstract]   [Full Text] [Related]  

  • 15. X. The economic cost of ESRD and Medicare spending for alternative modalities of treatment.
    Am J Kidney Dis; 1999 Aug; 34(2 Suppl 1):S124-39. PubMed ID: 10431009
    [No Abstract]   [Full Text] [Related]  

  • 16. Is HCFA's reimbursement policy controlling quality of care for end-stage renal disease patients?
    Lockridge RS; McKinney JK
    ASAIO J; 2001; 47(5):466-8. PubMed ID: 11575817
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic evaluation of dialysis therapies.
    Klarenbach S; Manns B
    Semin Nephrol; 2009 Sep; 29(5):524-32. PubMed ID: 19751898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
    Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
    BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of the treatment of end-stage renal disease in Brazil.
    Sesso R; Eisenberg JM; Stabile C; Draibe S; Ajzen H; Ramos O
    Int J Technol Assess Health Care; 1990; 6(1):107-14. PubMed ID: 2113888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of end stage renal disease treatment.
    de Wit GA; Ramsteijn PG; de Charro FT
    Health Policy; 1998 Jun; 44(3):215-32. PubMed ID: 10182294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.